[Relationship between plasma cortistatin and coronary heart disease]

Area of Science:

• Cardiovascular Medicine
• Endocrinology
• Biochemistry

Context:

• Coronary heart disease (CHD) is a leading cause of mortality worldwide.
• Understanding novel biomarkers for CHD is crucial for risk stratification and management.
• Cortistatin (CST) is a recently identified peptide with potential roles in cardiovascular physiology.

Purpose:

• To investigate the association between plasma cortistatin (CST) levels and coronary heart disease (CHD).
• To identify clinical factors influencing CST levels in patients with and without CHD.
• To assess the impact of percutaneous coronary intervention (PCI) on CST levels.

Summary:

• Plasma CST levels were significantly higher in CHD patients compared to healthy controls.
• PCI procedure did not alter CST levels.
• CST levels showed no correlation with fasting blood glucose, hsCRP, LVEF, or lesion severity.
• Triglyceride and total cholesterol levels negatively correlated with CST, while a history of diabetes mellitus (DM) or myocardial infarction (MI) positively correlated with CST.

Impact:

• Elevated CST levels in CHD patients suggest its potential involvement in CHD pathogenesis.
• CST may serve as a novel biomarker for CHD.
• Further research is warranted to elucidate the precise role of CST in cardiovascular disease.
• Understanding CST's relationship with metabolic factors and prior cardiac events could inform therapeutic strategies.